갑상선 질환 치료 시장 규모, 점유율, 성장 분석 : 유형별, 약제별, 투여 경로별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Thyroid Gland Disorders Treatment Market size was valued at USD 2.7 Billion in 2024 and is poised to grow from USD 2.81 Billion in 2025 to USD 3.85 Billion by 2033, growing at a CAGR of 4% during the forecast period (2026-2033).

The global thyroid gland disorders treatment market is experiencing significant growth, driven by an increase in prevalent conditions like hyperthyroidism, an aging population, advancements in medical technology, and heightened awareness regarding early diagnosis and treatment. The introduction of personalized medicine and targeted therapies further enriches the market landscape, with North America and Europe holding substantial share due to higher incidence rates and healthcare expenditure. Emerging economies in Latin America and Asia-Pacific are poised for notable growth, supported by improved healthcare infrastructures and awareness initiatives. The adoption of telemedicine for endocrinology consultations and routine care enhances accessibility, especially where specialist services are scarce. Challenges, such as limited diagnostic resources and high treatment costs, may hinder progress, yet the market's potential growth remains robust.

Top-down and bottom-up approaches were used to estimate and validate the size of the Thyroid Gland Disorders Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Thyroid Gland Disorders Treatment Market Segments Analysis

Global Thyroid Gland Disorders Treatment Market is segmented by Type, Drug, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Hypothyroidism and Hyperthyroidism. Based on Drug, the market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based compounds and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Others. Based on Distribution Channel, the market is segmented into Wholesale Distribution, Retail Stores, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Thyroid Gland Disorders Treatment Market

The rising prevalence of thyroid disorders globally is significantly driving the demand for treatment options. Conditions such as hyperthyroidism, hypothyroidism, and thyroid cancer are increasingly being diagnosed, largely due to heightened stress levels and lifestyle changes affecting individuals. Furthermore, environmental factors have contributed to the surge in these health issues. This growing incidence of thyroid-related ailments has created an urgent need for effective therapies and interventions, leading to an expansion in the market dedicated to treating thyroid gland disorders. Healthcare providers and pharmaceutical companies are responding to the escalating requirement for specialized medical care in this area.

Restraints in the Thyroid Gland Disorders Treatment Market

The financial burden associated with thyroid gland disorder treatments poses a significant restraint in this market. Patients undergoing long-term therapies, such as radioactive iodine treatments or surgical interventions, often face substantial costs for their prescriptions and procedures. This financial strain can be particularly pronounced for individuals in underserved regions or those without adequate health insurance coverage. Consequently, many patients may experience challenges in accessing necessary treatments, ultimately limiting their options and impacting overall patient outcomes. Addressing the affordability and accessibility of these treatment modalities is crucial for improving care for those affected by thyroid disorders.

Market Trends of the Thyroid Gland Disorders Treatment Market

The thyroid gland disorders treatment market is experiencing a significant transformation driven by increasing incidence rates worldwide. This surge in demand has prompted market players to focus on developing innovative treatment options that enhance patient care. Pharmaceutical companies are investing heavily in research and development, aiming to introduce more effective and affordable therapies tailored to individual needs. As new treatment modalities emerge, manufacturers are prioritizing improved patient outcomes, seeking to enhance quality of life while minimizing adverse effects. This trend underscores a commitment to addressing the complexities of thyroid disorders, fostering a robust landscape for ongoing advancements and therapeutic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Thyroid Gland Disorders Treatment Market Size by Type & CAGR (2026-2033)

• Market Overview
• Hypothyroidism
• Hyperthyroidism

Global Thyroid Gland Disorders Treatment Market Size by Drug & CAGR (2026-2033)

• Market Overview
• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-based compounds
• Others

Global Thyroid Gland Disorders Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Others

Global Thyroid Gland Disorders Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Wholesale Distribution
• Retail Stores
• Online Pharmacy
• Others

Global Thyroid Gland Disorders Treatment Market Size & CAGR (2026-2033)

• North America (Type, Drug, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jerome Stevens Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lannett Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations